BackImmunityBio Overview
ImmunityBio Inc

ImmunityBio Target Price

See ImmunityBio's analyst price targets ($15) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$8.64

Average Target Price

$15.0073.7% upside

2 analysts in the last 4 months

High: $16 | Low: $14

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-10-14Jefferies$1462.1% upsideOpen
2026-10-14Piper Sandler$1685.3% upsideOpen
2026-05-08BTIG$1239% upsideOpen
2026-03-04Piper SandlerEdward Tenthoff$1239% upsideOpen
2026-02-23H.C. Wainwright$1573.7% upsideOpen
2026-01-20Piper Sandler$718.9% downsideOpen
2025-01-10BTIGJustin Zelin$630.5% downsideOpen
2022-08-03JefferiesKelly Shi$87.4% downsideOpen

ImmunityBio (IBRX) FAQ

ImmunityBio (IBRX) currently reports a target price of $15. Use the charts on this page to explore ImmunityBio's target price history and peer comparisons.

Analysts' average 12-month price target for ImmunityBio is $15, about 73.7% upside from the current share price of $8.64. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $15, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ImmunityBio, and consider following IBRX for alerts when major investors trade the stock.

ImmunityBio is classified in the Healthcare sector. On target price, it currently shows $15. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IBRX with unrelated industries.